Home Archives July 2008 State wins case against Merck

State wins case against Merck

| Print |  Email
Tuesday, July 01, 2008

STATEWIDE Oregon’s lead role in a record-breaking settlement with Merck & Co. over deceptive marketing for the anti-inflammatory drug Vioxx represents the latest skirmish in an ongoing campaign against Big Pharma that has earned the state more than $8.5 million.

After leading a three-year, 30-state investigation into deceptive advertisements downplaying the health risks associated with Vioxx, Oregon received $2.8 million of the record $58 million paid out by Merck. The judgment banned Merck from manipulating data when marketing to physicians, “ghost writing” articles for medical journals and failing to disclose conflicts of interest among doctors who study and promote drugs on behalf of the company.

The Vioxx settlement reflects growing concerns over how drug companies hook consumers on prescription drugs. Drug giants have poured billions into “demand creation” since the federal government loosened rules prohibiting “direct-to-consumer” advertising in 1997. In 2007 Oregon was the lead state in an $8 million settlement against Bayer for minimizing the dangers of Baycol, and also was in on a $19.5 million settlement against Purdue Pharma regarding OxyContin.

State officials cannot comment about current cases involving major pharmaceutical firms, but Oregon’s campaign against Big Pharma is clearly far from finished. Leading the way has been assistant attorney general David Hart, who worked in health care prior to pursuing consumer law and is married to a pharmacist. Hart has served as lead investigator and negotiator on all of Oregon’s major drug company cases. “The money we’ve gotten in these settlements gets put to good use, but these cases aren’t about the money,” he says, “they’re about the rules we create and the light that we shed on these practices so that we can change them.”

Ken Johnson, vice president of the Pharmaceutical Research and Manufacturers of America, said in a prepared statement that drug companies “are committed to providing accurate, educational information to patients and health professionals about their medicines.”


BEN JACKLET


To comment, email This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

 

More Articles

Two Sides of the Coin

Contributed Blogs
Friday, September 26, 2014
0926 iphone6-thumbBY JASON NORRIS | GUEST BLOGGER

This post focuses on the recent release of the new Apple iPhone as well as Alibaba's IPO, the largest U.S. IPO in history.


Read more...

October surprise

News
Sunday, October 12, 2014
roundup-logo-thumb-14BY LINDA BAKER

Cylvia Hayes, tabloid vs. watchdog journalism and the looming threat of a Cascadia earthquake.


Read more...

The Diaspora

October 2014
Thursday, September 25, 2014
BY LEE VAN DER VOO

Former newspaper reporters move into brand journalism.


Read more...

The Rail Baron

October 2014
Thursday, September 25, 2014
BY LINDA BAKER

Oil is gushing out of the U.S. and Canada, and much of it is coming from places that don’t have pipeline infrastructure. So it’s being shipped by rail.


Read more...

Revenge Forestry

November/December 2014
Tuesday, October 14, 2014
BY JONATHAN FROCHTZWAJG

A flare-up in the Elliott Forest raises questions about détente in Oregon’s timber wars.


Read more...

Shuffling the Deck

November/December 2014
Wednesday, October 22, 2014
BY JON BELL

Oregon tribes still bet on casinos.


Read more...

Growing a mobility cluster

News
Friday, October 31, 2014
0414 bikes bd2f6052BY LINDA BAKER | OB EDITOR

Why are there so few transportation startups in Portland?  The city’s leadership in bike, transit and pedestrian transportation has been well-documented.  But that was then — when government and nonprofits paved the way for a new, less auto centric way of life.


Read more...
Oregon Business magazinetitle-sponsored-links-02
SPONSORED LINKS